Crispr Therapeutics AG (CRSP) Receives $65.03 Consensus Target Price from Analysts

Crispr Therapeutics AG (NASDAQ:CRSP) has received a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $65.03.

A number of analysts have recently commented on the company. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 13th. Zacks Investment Research downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Wednesday, August 8th. Raymond James assumed coverage on Crispr Therapeutics in a research note on Thursday, September 20th. They issued an “underperform” rating on the stock. Finally, Citigroup dropped their price objective on Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating on the stock in a research note on Friday, August 24th.

CRSP opened at $36.56 on Friday. Crispr Therapeutics has a one year low of $16.51 and a one year high of $73.90. The firm has a market capitalization of $2.09 billion, a PE ratio of -21.38 and a beta of 3.70.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.19). Crispr Therapeutics had a negative return on equity of 39.58% and a negative net margin of 245.57%. The firm had revenue of $1.09 million during the quarter, compared to the consensus estimate of $1.47 million. On average, research analysts forecast that Crispr Therapeutics will post -2.92 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC grew its holdings in shares of Crispr Therapeutics by 123.8% in the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after acquiring an additional 1,300 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Crispr Therapeutics by 91.9% in the 1st quarter. Royal Bank of Canada now owns 26,620 shares of the company’s stock worth $1,217,000 after acquiring an additional 12,751 shares during the last quarter. First Mercantile Trust Co. acquired a new position in shares of Crispr Therapeutics in the 2nd quarter worth $141,000. BlackRock Inc. grew its holdings in shares of Crispr Therapeutics by 3.6% in the 1st quarter. BlackRock Inc. now owns 572,218 shares of the company’s stock worth $26,156,000 after acquiring an additional 19,660 shares during the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new position in shares of Crispr Therapeutics in the 2nd quarter worth $322,000. Institutional investors and hedge funds own 39.13% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Further Reading: Why do company’s buyback their stock?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply